(CNMD) CONMED - Overview

Sector: Healthcare | Industry: Medical Devices | Exchange: NYSE (USA) | Market Cap: 1.077m USD | Total Return: -38.1% in 12m

Surgical Devices, Orthopedics, General Surgery, Endoscopy
Total Rating 39
Safety 87
Buy Signal -0.75
Medical Devices
Industry Rotation: -6.1
Market Cap: 1.08B
Avg Turnover: 14.0M USD
ATR: 4.65%
Peers RS (IBD): 17.8
Risk 5d forecast
Volatility41.3%
Rel. Tail Risk-3.68%
Reward TTM
Sharpe Ratio-1.08
Alpha-62.28
Character TTM
Beta1.075
Beta Downside0.843
Drawdowns 3y
Max DD74.82%
CAGR/Max DD-0.42
EPS (Earnings per Share) EPS (Earnings per Share) of CNMD over the last years for every Quarter: "2021-03": 0.63, "2021-06": 0.71, "2021-09": 0.8, "2021-12": 1.07, "2022-03": 0.7, "2022-06": 0.76, "2022-09": 0.77, "2022-12": 0.42, "2023-03": 0.66, "2023-06": 0.83, "2023-09": 0.9, "2023-12": 1.06, "2024-03": 0.79, "2024-06": 0.98, "2024-09": 1.05, "2024-12": 1.34, "2025-03": 0.95, "2025-06": 0.69, "2025-09": 1.08, "2025-12": 1.43,
EPS CAGR: 20.98%
EPS Trend: 64.7%
Last SUE: 0.78
Qual. Beats: 0
Revenue Revenue of CNMD over the last years for every Quarter: 2021-03: 232.677, 2021-06: 255.161, 2021-09: 248.827, 2021-12: 273.97, 2022-03: 242.327, 2022-06: 277.19, 2022-09: 275.088, 2022-12: 250.867, 2023-03: 295.468, 2023-06: 317.652, 2023-09: 304.578, 2023-12: 327.045, 2024-03: 312.273, 2024-06: 332.097, 2024-09: 316.701, 2024-12: 345.944, 2025-03: 321.256, 2025-06: 342.345, 2025-09: 337.926, 2025-12: 373.198,
Rev. CAGR: 12.20%
Rev. Trend: 88.8%
Last SUE: 1.46
Qual. Beats: 1

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Description: CNMD CONMED

CONMED Corporation (CNMD) is a medical technology company specializing in surgical devices and equipment. The company operates in the Health Care Equipment sector, which is characterized by ongoing innovation and product development to meet evolving medical needs.

CNMDs product portfolio spans orthopedic surgery, general surgery, and endoscopic technologies. Orthopedic offerings include soft tissue repair systems and powered resection instruments. General surgery products feature insufflation systems, smoke removal devices, and various endomechanical tools for minimally invasive procedures. Endoscopic technologies cover therapeutic and diagnostic products for gastroenterology, along with patient monitoring electrodes.

The companys business model involves direct sales to hospitals and surgery centers, supplemented by medical specialty distributors. This dual-channel approach is common for medical device manufacturers seeking broad market penetration.

To gain further insights into CNMDs market position and financial health, consider exploring its detailed performance metrics on ValueRay.

Headlines to Watch Out For
  • Orthopedic product sales drive revenue growth
  • General surgery device demand impacts profitability
  • Regulatory approvals affect new product launches
  • Healthcare spending trends influence equipment adoption
Piotroski VR‑10 (Strict) 5.0
Net Income: 47.1m TTM > 0 and > 6% of Revenue
FCF/TA: 0.06 > 0.02 and ΔFCF/TA -0.18 > 1.0
NWC/Revenue: 26.03% < 20% (prev 27.69%; Δ -1.66% < -1%)
CFO/TA 0.07 > 3% & CFO 170.7m > Net Income 47.1m
Net Debt (794.1m) to EBITDA (176.5m): 4.50 < 3
Current Ratio: 2.14 > 1.5 & < 3
Outstanding Shares: last quarter (31.0m) vs 12m ago -0.26% < -2%
Gross Margin: 54.59% > 18% (prev 0.56%; Δ 5.40k% > 0.5%)
Asset Turnover: 59.36% > 50% (prev 56.67%; Δ 2.68% > 0%)
Interest Coverage Ratio: 3.29 > 6 (EBITDA TTM 176.5m / Interest Expense TTM 31.1m)
Altman Z'' 2.57
A: 0.15 (Total Current Assets 672.9m - Total Current Liabilities 315.0m) / Total Assets 2.33b
B: 0.25 (Retained Earnings 588.8m / Total Assets 2.33b)
C: 0.04 (EBIT TTM 102.2m / Avg Total Assets 2.32b)
D: 0.42 (Book Value of Equity 542.8m / Total Liabilities 1.29b)
Altman-Z'' Score: 2.57 = A
Beneish M -3.04
DSRI: 0.99 (Receivables 247.8m/237.7m, Revenue 1.37b/1.31b)
GMI: 1.03 (GM 54.59% / 56.08%)
AQI: 0.98 (AQ_t 0.66 / AQ_t-1 0.67)
SGI: 1.05 (Revenue 1.37b / 1.31b)
TATA: -0.05 (NI 47.1m - CFO 170.7m) / TA 2.33b)
Beneish M-Score: -3.04 (Cap -4..+1) = AA
What is the price of CNMD shares? As of April 07, 2026, the stock is trading at USD 34.08 with a total of 384,157 shares traded.
Over the past week, the price has changed by +1.76%, over one month by -14.59%, over three months by -21.64% and over the past year by -38.06%.
Is CNMD a buy, sell or hold? CONMED has received a consensus analysts rating of 3.33. Therefor, it is recommend to hold CNMD.
  • StrongBuy: 0
  • Buy: 2
  • Hold: 4
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the CNMD price?
Analysts Target Price 44.2 29.7%
CONMED (CNMD) - Fundamental Data Overview as of 06 April 2026
P/E Trailing = 23.0397
P/E Forward = 27.1739
P/S = 0.7837
P/B = 1.0383
P/EG = 1.8437
Revenue TTM = 1.37b USD
EBIT TTM = 102.2m USD
EBITDA TTM = 176.5m USD
Long Term Debt = 834.2m USD (from longTermDebt, last quarter)
Short Term Debt = 712k USD (from shortTermDebt, last quarter)
Debt = 834.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 794.1m USD (from netDebt column, last quarter)
Enterprise Value = 1.87b USD (1.08b + Debt 834.9m - CCE 40.8m)
Interest Coverage Ratio = 3.29 (Ebit TTM 102.2m / Interest Expense TTM 31.1m)
EV/FCF = 12.40x (Enterprise Value 1.87b / FCF TTM 150.9m)
FCF Yield = 8.06% (FCF TTM 150.9m / Enterprise Value 1.87b)
FCF Margin = 10.98% (FCF TTM 150.9m / Revenue TTM 1.37b)
Net Margin = 3.42% (Net Income TTM 47.1m / Revenue TTM 1.37b)
Gross Margin = 54.59% ((Revenue TTM 1.37b - Cost of Revenue TTM 624.2m) / Revenue TTM)
Gross Margin QoQ = 58.49% (prev 49.16%)
Tobins Q-Ratio = 0.80 (Enterprise Value 1.87b / Total Assets 2.33b)
Interest Expense / Debt = 0.88% (Interest Expense 7.37m / Debt 834.9m)
Taxrate = 42.78% (12.5m / 29.3m)
NOPAT = 58.5m (EBIT 102.2m * (1 - 42.78%))
Current Ratio = 2.14 (Total Current Assets 672.9m / Total Current Liabilities 315.0m)
Debt / Equity = 0.81 (Debt 834.9m / totalStockholderEquity, last quarter 1.03b)
Debt / EBITDA = 4.50 (Net Debt 794.1m / EBITDA 176.5m)
Debt / FCF = 5.26 (Net Debt 794.1m / FCF TTM 150.9m)
Total Stockholder Equity = 1.01b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.03% (Net Income 47.1m / Total Assets 2.33b)
RoE = 4.68% (Net Income TTM 47.1m / Total Stockholder Equity 1.01b)
RoCE = 5.56% (EBIT 102.2m / Capital Employed (Equity 1.01b + L.T.Debt 834.2m))
RoIC = 3.13% (NOPAT 58.5m / Invested Capital 1.87b)
WACC = 5.73% (E(1.08b)/V(1.91b) * Re(9.78%) + D(834.9m)/V(1.91b) * Rd(0.88%) * (1-Tc(0.43)))
Discount Rate = 9.78% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.75%
[DCF] Terminal Value 86.94% ; FCFF base≈152.1m ; Y1≈161.9m ; Y5≈194.7m
[DCF] Fair Price = 160.6 (EV 5.75b - Net Debt 794.1m = Equity 4.95b / Shares 30.8m; r=6.0% [WACC]; 5y FCF grow 7.17% → 3.0% )
EPS Correlation: 64.71 | EPS CAGR: 20.98% | SUE: 0.78 | # QB: 0
Revenue Correlation: 88.82 | Revenue CAGR: 12.20% | SUE: 1.46 | # QB: 1
EPS next Quarter (2026-06-30): EPS=1.09 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=6
EPS current Year (2026-12-31): EPS=4.35 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=+2 | Growth EPS=-5.1% | Growth Revenue=-1.1%
EPS next Year (2027-12-31): EPS=4.93 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=+0 | Growth EPS=+13.1% | Growth Revenue=+5.5%
[Analyst] Revisions Ratio: +0.33 (2 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.4% (Discount Rate 9.8% - Earnings Yield 4.3%)
[Growth] Growth Spread = -5.9% (Analyst -0.5% - Implied 5.4%)
External Resources
Dataroma Stockcircle